Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/26 05:05:12」(JST)

wiki en

Prednisolone is a synthetic glucocorticoid, a derivative of cortisol, used to treat a variety of inflammatory and autoimmune conditions and some cancers. It is the active metabolite of the drug prednisone^[1] and is used especially in patients with liver failure, as these individuals are unable to metabolize prednisone into active prednisolone; it is primarily metabolized via the liver enzyme, 11-β-hydroxydehydrogenase.^[2] Adverse effects are not generally seen with short term therapy, but weight gain, impaired immune response, and behavioral disturbances commonly occur with longer durations of treatment.^[2]

It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.^[3]

Medical uses

Prednisolone is a corticosteroid drug with predominant glucocorticoid and low mineralocorticoid activity, making it useful for the treatment of a wide range of inflammatory and autoimmune conditions^[4] such as asthma,^[5] uveitis, pyoderma gangrenosum, rheumatoid arthritis, ulcerative colitis, pericarditis, temporal arteritis and Crohn's disease, Bell's palsy, multiple sclerosis,^[6] cluster headaches, vasculitis, acute lymphoblastic leukemia and autoimmune hepatitis,^[7] systemic lupus erythematosus, Kawasaki disease,^[8] dermatomyositis,^[9] and sarcoidosis.^[10]

Prednisolone acetate ophthalmic suspension (eye drops) is an adrenocortical steroid product, prepared as a sterile ophthalmic suspension and used to reduce swelling, redness, itching, and allergic reactions affecting the eye.^[11]^[12]

Prednisolone can also be used for allergic reactions ranging from seasonal allergies to drug allergic reactions.^[13]

Prednisolone can also be used as an immunosuppressive drug for organ transplants.^[9]^[14]

Prednisolone in lower doses can be used in cases of primary adrenal insufficiency (Addison's disease).^[15]^[16]

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and, it is presumed, delay or slow healing.^[17] They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation with inflammation.^[18]

Adverse effects

There are several adverse reaction from the use of prednisolone:

Increase appetite, weight gain, nausea, and malaise
Increase risk of infection
Cardiovascular events in children
Dermatological effects including reddening of face, bruising/ skin discoloration, impaired wound healing, thinning of skin, skin rash, fluid build up and abnormal hair growth
Hyperglycemia; patients with diabetes may need increase insulin or diabetic therapies
Menstrual abnormalities
Less response to hormones especially during stressful instances such as surgery or illness.
Change in electrolytes: rise in blood pressure, increase sodium and low potassium leading to alkalosis
GI system effects: Swelling of stomach lining, reversible increase in liver enzymes and risk of stomach ulcers
Muscular and skeletal abnormalities such as muscle weakness and loss, osteoporosis, long bone fractures, tendon rupture and back fractures.
Neurological effects include involuntary movements (convulsions), headaches, and vertigo
Behavioral disturbances ^[19]

Nasal septum perforation and bowel perforation are also notable adverse effects that restrict steroids' use in some pathologic conditions.^[20]^[21]

Withdrawal from prednisolone after long term or high dose use can lead to adrenal insufficiency.^[19]

Pregnancy and breastfeeding

Although there are no major human studies of prednisolone use in pregnant women, studies in several animals show that it may cause birth defects including increase cleft palate. Prednisolone should be used in pregnant women when benefits outweigh the risks and children born from mothers using prednisolone during pregnancy should be monitored for impaired adrenal function.

Prednisolone is found in breast milk of mothers taking prednisolone.^[19]

Mechanism of action

As a synthetic glucocorticoid (GC), its lipophilic structure allows for easy passage through the cell membrane where it then binds to its respective glucocorticoid receptor (GCR) located in the cytoplasm. Upon binding, formation of the GC/GCR complex causes dissociation of chaperone proteins from the glucocorticoid receptor enabling the GC/GCR complex to translocate inside the nucleus. This process occurs within 20 minutes of binding. Once inside the nucleus, the homodimer GC/GCR complex binds to specific DNA binding-sites known as glucocorticoid response elements (GREs) resulting in gene expression or inhibition. Complex binding to positive GREs leads to synthesis of anti-inflammatory proteins while binding to negative GREs block the transcription of inflammatory genes.^[22]

Society and culture

Dosage forms

In the United States

Prednisolone sodium posphate oral solution (Pediapred)^[19]
Prednisolone acetate oral suspension (Flo-Pred)^[23]
Prednisolone oral tablets (Millipred)^[13]
Prednisolone sodium phosphate oral dissolving tablets (Orapred)^[24]

Athletics

As a glucocorticosteroid, unauthorized or ad-hoc use of prednisolone during competition via oral, intravenous, intramuscular or rectal routes is banned under WADA anti-doping rules.^[25] The drug may be used in competition with a TUE (Therapeutic Use Exemption), in compliance with WADA regulations. Local or topical use of prednisolone during competition as well as any use out of competition is not regulated.^[25]

References

^ Davis M, Williams R, Chakraborty J, et al. (June 1978). "Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability". British Journal of Clinical Pharmacology 5 (6): 501–5. doi:10.1111/j.1365-2125.1978.tb01664.x. PMC 1429358. PMID 656293.
^ ^a ^b Frey, Brigitte (March 1985). "Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection.". Transplantation 39: 270–4. doi:10.1160/TH11-09-0672. PMID 3883592. |access-date= requires |url= (help)
^ "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
^ Czock D, Keller F, Rasche FM, Häussler U (2005). "Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids". Clin Pharmacokinet 44 (1): 61–98. doi:10.2165/00003088-200544010-00003. PMID 15634032.
^ Fiel SB, Vincken W (Jun 2006). "Systemic corticosteroid therapy for acute asthma exacerbations". J Asthma 43 (5): 321–31. doi:10.1080/02770900600567163. PMID 16801135.
^ Thrower BW (Jan 2009). "Relapse management in multiple sclerosis". Neurologist 15 (1): 1–5. doi:10.1097/NRL.0b013e31817acf1a. PMID 19131851.
^ Lambrou GI, Vlahopoulos S, Papathanasiou C, Papanikolaou M, Karpusas M, Zoumakis E, Tzortzatou-Stathopoulou F (2009). "Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: Relation to early gene expression". Leuk Res. 33 (12): 1684–95. doi:10.1016/j.leukres.2009.04.018. PMID 19450877.
^ Miura M, Tamame T, Naganuma T, Chinen S, Matsuoka M, Ohki H (2011). "Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy". Paediatrics & Child Health 16 (8): 479–84. PMC 3202387. PMID 23024586.
^ ^a ^b Product Information: ORAPRED ODT(TM) orally disintegrating tablets, prednisolone sodium phosphate orally disintegrating tablets. Cima Labs Inc, Alpharetta, GA, 2006.
^ Gera, Kamal; Gupta, Nitesh; Ahuja, Anuradha; Shah, Ashok (2014-04-30). "Acute alveolar sarcoidosis presenting with hypoxaemic respiratory failure". BMJ Case Reports 2014: bcr2013202247. doi:10.1136/bcr-2013-202247. ISSN 1757-790X. PMC 4024548. PMID 24789154.
^ "Pred Forte Package Insert" (PDF).
^ Product Information: OMNIPRED(TM) ophthalmic suspension, prednisolone acetate ophthalmic suspension. Alcon Laboratories Inc, Fort Worth, TX, 2005
^ ^a ^b "Millipred tablets package insert" (PDF).
^ Vethe, Nils; Midtvedt, Karsten; Åsberg, Anders; Amundsen, Rune; Bergan, Stein. "Legemiddelinteraksjoner og immunsuppresjon hos organtransplanterte". Tidsskrift for Den norske legeforening 131 (20): 2000–2003. doi:10.4045/tidsskr.11.0138.
^ Husebye, E. S.; Allolio, B.; Arlt, W.; Badenhoop, K.; Bensing, S.; Betterle, C.; Falorni, A.; Gan, E. H.; Hulting, A.-L. (2014-02-01). "Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency". Journal of Internal Medicine 275 (2): 104–115. doi:10.1111/joim.12162. ISSN 1365-2796.
^ AMA Department of Drugs: AMA Drug Evaluations, 6th. American Medical Association, Chicago, IL, 1986.
^ Schwiebert, L. M.; Beck, L. A.; Stellato, C.; Bickel, C. A.; Bochner, B. S.; Schleimer, R. P.; Schwiebert, L. A. (1996-01-01). "Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions". The Journal of Allergy and Clinical Immunology 97 (1 Pt 2): 143–152. doi:10.1016/s0091-6749(96)80214-4. ISSN 0091-6749. PMID 8568145.
^ Lee, Sang Hag (2015). "Mechanisms of Glucocorticoid Action in Chronic Rhinosinusitis". Allergy, Asthma & Immunology Research 7 (6): 534–7. doi:10.4168/aair.2015.7.6.534. PMC 4605925. PMID 26333699.
^ ^a ^b ^c ^d "PEDIAPRED" (PDF).
^ "Bowel Perforation in Steroid-Treated Patients"
^ "Intranasal steroids and septum perforation--an overlooked complication?"
^ Stahn, Cindy (17 May 2007). "Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists" (PDF). Molecular and Cellular Endocrinology 275: 71–78. doi:10.1016/j.mce.2007.05.019.
^ "Flo-Pred Package Insert" (PDF).
^ "Package Insert for Orapred ODT" (PDF).
^ ^a ^b "The 2011 Prohibited List".

English Journal

Prednisone and prednisolone bioavailability in renal transplant patients.

Gambertoglio JG, Frey FJ, Holford NH, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O Jr, Amend WJ Jr.
Kidney international.Kidney Int.1982 Apr;21(4):621-6.
Prednisone and prednisolone are drugs with the potential for therapeutic inequivalence due to bioavailability problems. The objective of our study was to compare the systemic bioavailability of prednisolone from oral prednisone and prednisolone. Nine kidney transplant patients receiving prednisone (
PMID 7047863

NEW and Nonofficial Drugs; prednisolone phosphate sodium (hydeltrasol).

[No authors listed]
Journal of the American Medical Association.J Am Med Assoc.1959 Sep 5;171:51-3.
PMID 13857325

Related Pictures

Zyban Oral Tablet, Extended Release 12 Prelone - patient information, description Merck Hydeltrasol Drug Tin Tray | eBay Folk Art on Pinterest | Folk Art hydeltrasol octreotide injection inferior AsmalPred Plus, Bubbli-Pred, Flo-Pred 21-phosphate;Dojilon;Hefasolon;Hydeltrasol Hydase - patient information, description

★リンクテーブル★

リンク元

「プレドニゾロン」

Prednisolone
Systematic (IUPAC) name
	(11β)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a682794
License data	US FDA: prednisolone;
Pregnancy; category	AU: A; US: C (Risk not ruled out); ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Biological half-life	2-3 hours
Excretion	urine
Identifiers
CAS Number	50-24-8
ATC code	A07EA01 (WHO) C05AA04 (WHO), D07AA03 (WHO), H02AB06 (WHO), R01AD02 (WHO), S01BA04 (WHO), S02BA03 (WHO), S03BA02 (WHO)
PubChem	CID 5755
IUPHAR/BPS	2866
DrugBank	DB00860
ChemSpider	5552
UNII	9PHQ9Y1OLM
KEGG	D00472
ChEBI	CHEBI:8378
ChEMBL	CHEMBL131
Synonyms	11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a] phenanthren-3-one
Chemical data
Formula	C21H28O5
Molar mass	360.444 g/mol
	SMILES O=C\1\C=C/[C@]4(/C(=C/1)CC[C@@H]2[C@@H]4[C@@H](O)C[C@@]3([C@@](O)(C(=O)CO)CC[C@@H]23)C)C ;
	InChI InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 ; Key:OIGNJSKKLXVSLS-VWUMJDOOSA-N ;
(verify)

　　[★]

英: prednisolone, PSL
化: コハク酸プレドニゾロン、コハク酸プレドニゾロンナトリウム, prednisolone sodium succinate、酢酸プレドニゾロン
商: プレドニゾロン、プレドニン, Predonine、Delta Cortef、Hydeltrasol、Predalone; PSゾロン、クロマイ-P、コールタイジン、コハクサニン、スピラゾン、ハイセチンP、ビスオ、ファルネゾン、プレドニン、プレドネマ、プレドハン、プレロン、ユーメトン、リドメックスコーワ
関: 副腎皮質ホルモン、糖質コルチコイド。プレドニゾン

概念

合成糖質副腎皮質ホルモン
ヒドロコルチゾンの誘導体

"prednisone" is a prodrug that is converted by the liver into "prednisolone", which is the active drug and also a steroid.

添付文書

※プレドニゾロン錠5mg「トーワ」

http://www.info.pmda.go.jp/go/pack/2456001F1400_1_03/2456001F1400_1_03?view=body

[Davis-1] Davis M, Williams R, Chakraborty J, et al. (June 1978). "Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability". British Journal of Clinical Pharmacology 5 (6): 501–5. doi:10.1111/j.1365-2125.1978.tb01664.x. PMC 1429358. PMID 656293.

[:3-2] Frey, Brigitte (March 1985). "Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection.". Transplantation 39: 270–4. doi:10.1160/TH11-09-0672. PMID 3883592. |access-date= requires |url= (help)

[WHO2015E-3] "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.

[4] Czock D, Keller F, Rasche FM, Häussler U (2005). "Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids". Clin Pharmacokinet 44 (1): 61–98. doi:10.2165/00003088-200544010-00003. PMID 15634032.

[5] Fiel SB, Vincken W (Jun 2006). "Systemic corticosteroid therapy for acute asthma exacerbations". J Asthma 43 (5): 321–31. doi:10.1080/02770900600567163. PMID 16801135.

[6] Thrower BW (Jan 2009). "Relapse management in multiple sclerosis". Neurologist 15 (1): 1–5. doi:10.1097/NRL.0b013e31817acf1a. PMID 19131851.

[7] Lambrou GI, Vlahopoulos S, Papathanasiou C, Papanikolaou M, Karpusas M, Zoumakis E, Tzortzatou-Stathopoulou F (2009). "Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: Relation to early gene expression". Leuk Res. 33 (12): 1684–95. doi:10.1016/j.leukres.2009.04.018. PMID 19450877.

[8] Miura M, Tamame T, Naganuma T, Chinen S, Matsuoka M, Ohki H (2011). "Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy". Paediatrics & Child Health 16 (8): 479–84. PMC 3202387. PMID 23024586.

[Cima_Labs_Inc_2006-9] Product Information: ORAPRED ODT(TM) orally disintegrating tablets, prednisolone sodium phosphate orally disintegrating tablets. Cima Labs Inc, Alpharetta, GA, 2006.

[10] Gera, Kamal; Gupta, Nitesh; Ahuja, Anuradha; Shah, Ashok (2014-04-30). "Acute alveolar sarcoidosis presenting with hypoxaemic respiratory failure". BMJ Case Reports 2014: bcr2013202247. doi:10.1136/bcr-2013-202247. ISSN 1757-790X. PMC 4024548. PMID 24789154.

[11] "Pred Forte Package Insert" (PDF).

[12] Product Information: OMNIPRED(TM) ophthalmic suspension, prednisolone acetate ophthalmic suspension. Alcon Laboratories Inc, Fort Worth, TX, 2005

[:0-13] "Millipred tablets package insert" (PDF).

[14] Vethe, Nils; Midtvedt, Karsten; Åsberg, Anders; Amundsen, Rune; Bergan, Stein. "Legemiddelinteraksjoner og immunsuppresjon hos organtransplanterte". Tidsskrift for Den norske legeforening 131 (20): 2000–2003. doi:10.4045/tidsskr.11.0138.

[15] Husebye, E. S.; Allolio, B.; Arlt, W.; Badenhoop, K.; Bensing, S.; Betterle, C.; Falorni, A.; Gan, E. H.; Hulting, A.-L. (2014-02-01). "Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency". Journal of Internal Medicine 275 (2): 104–115. doi:10.1111/joim.12162. ISSN 1365-2796.

[16] AMA Department of Drugs: AMA Drug Evaluations, 6th. American Medical Association, Chicago, IL, 1986.

[17] Schwiebert, L. M.; Beck, L. A.; Stellato, C.; Bickel, C. A.; Bochner, B. S.; Schleimer, R. P.; Schwiebert, L. A. (1996-01-01). "Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions". The Journal of Allergy and Clinical Immunology 97 (1 Pt 2): 143–152. doi:10.1016/s0091-6749(96)80214-4. ISSN 0091-6749. PMID 8568145.

[18] Lee, Sang Hag (2015). "Mechanisms of Glucocorticoid Action in Chronic Rhinosinusitis". Allergy, Asthma & Immunology Research 7 (6): 534–7. doi:10.4168/aair.2015.7.6.534. PMC 4605925. PMID 26333699.

[:2-19] "PEDIAPRED" (PDF).

[20] "Bowel Perforation in Steroid-Treated Patients"

[21] "Intranasal steroids and septum perforation--an overlooked complication?"

[22] Stahn, Cindy (17 May 2007). "Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists" (PDF). Molecular and Cellular Endocrinology 275: 71–78. doi:10.1016/j.mce.2007.05.019.

[23] "Flo-Pred Package Insert" (PDF).

[24] "Package Insert for Orapred ODT" (PDF).

[:1-25] "The 2011 Prohibited List".

匿名

検索

案内

案内

Hydeltrasol